Thorsten Fuereder
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Risk Factors, Biomarkers, and Risk Assessment Models for Prediction of Venous Thromboembolism in Ambulatory Patients with Advanced Lung Cancer.
Journal: Hamostaseologie
Published: June 09, 2026
Real-world evidence from a tertiary academic center: clinical characteristics, microbiology and outcomes of oncology patients with febrile neutropenia presenting to the emergency department.
Journal: BMC infectious diseases
Published: December 26, 2025
HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patients.
Journal: Breast (Edinburgh, Scotland)
Published: November 18, 2025
Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial.
Journal: ESMO open
Published: August 25, 2025
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.
Journal: The New England journal of medicine
Published: June 18, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: May 09, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: May 08, 2025
Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED study.
Journal: Research and practice in thrombosis and haemostasis
Published: April 08, 2025
Monotherapy With Immune Checkpoint Inhibitors in Patients With Recurrent and/or Metastatic Sinonasal Squamous Cell Carcinoma.
Journal: Cancer medicine
Published: January 24, 2025
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 16, 2024
Last Updated: 09/26/2026